Saturday, June 6, 2009

KPMG-IDMA seminar on opportunities & challenges for Indian pharma in Mumbai on June 9

Mumbai-The global consultancy firm KPMG, in collaboration with the Indian Drug Manufacturers' Association (IDMA), will organise a half day seminar on the opportunities and challenges for the Indian pharmaceutical industry in global markets on June 9, 2009 in Mumbai.The conference on 'Bringing Medicine to Global Markets - Opportunities and Challenges' is poised to provide insight on the regulatory perspectives, the price reporting methods and business challenges in various countries for the Indian pharma industry. The aim is to update the latest developments, opportunities and challenges in these markets, where the Indian companies have their business prospects active.The opening remarks will be delivered by N R Munjal, president, IDMA, Arpinder Singh, executive director, KPMG in India and Karen Harper, principal advisor, KPMG LLP by providing insight on the vision for the future of drug development, drug approval and audit methods in emerging markets. William Sarraille, partner, Sidley Austin LLP, will detail on the pharmaceutical price reporting, a must for companies operating in the United States. In the light of heavy fines levied by US for non-compliance, William Sarraille will deliver on review of VA Inspector General's requirements for written policies and procedures, methods to implement an internal audit and to face the VA's voluntary disclosure program.The challenges in developing an industry perspective global compliance program to meet the regulatory challenges and business challenges and to maintain best practices with a global overview will be elaborated by Abhiroop Gandhi, director of global compliance, Actelion Pharmaceuticals.The challenges faced by India Pharma to enter and expand operations in the regulated markets will be another topic to update the participants from the industry. The importance of developing a winning strategy, finding the right business model, managing risk/return equation and keeping a focus on the competency development for this will be elucidated by Sanjay Singh, associate director- corporate finance, KPMG India.A panel discussion on the emerging issues faced by pharma companies in India on protection of their Intellectual Property as well as FCPA and anti-bribery issues will be held following the session. The panel, consisting of V V Parsuram, vice- president - corporate governance, Dr Reddy's Lab, Adheesh Nargolkar, senior associate, AZB & Partners and Gaganpreet Singh Puri, director, KPMG in India, will also address some of the typical issues faced by pharma companies when operating in Indian Market, informed KPMG officials.

No comments:

Post a Comment